Cost Analysis of a Home Intravenous Antibiotic Program

A cost analysis of Outpatient Parenteral Antibiotic Therapy (OPAT): an Asian perspective

“…In contrast, cost savings of OPAT care reported in analyses in the literature were mostly determined through estimation. In these studies, actual costs associated with OPAT care were compared with the projected cost that would have been incurred had the OPAT patients received similar care, for the same duration, in an inpatient setting [3,7,[9][10][11].…”

“…Although OPAT brings many benefits to patients, arguably the primary reason for the increasing utilisation of this form of therapy is economic [5]. Cost analyses of OPAT programmes in the USA, Canada and several European countries have demonstrated that the use of OPAT over inpatient therapy results in financial benefits [3,[6][7][8][9][10][11], with savings reported to range from 18% to 87% [3,7,8]. These studies did not examine actual costs through the continuum of inpatient and outpatient care.…”

Quality-of-Life Assessment in an Outpatient Parenteral Antibiotic Program

“…Cost analysis of OPAT programs in the US, Canada, and other settings have been reported. 5, [8][9][10][11][12][13] An adult OPAT program was implemented at our hospital in 1995. 14 Patients are enrolled in the program if they have a proven or suspected infection requiring ≥1 parenter-al antimicrobials for an expected minimum duration of 5 days, are medically stable, have an acceptable venous access, demonstrate willingness and capability to perform the necessary self-management tasks, and live in a suitable home environment.…”

Outpatient Parenteral Antimicrobial Therapy Today

“…Comparison with hospitalization aside, little current information exists on which to base a pharmacoeconomic analysis of OPAT (Figure 3), although there have been a number of articles [38][39][40][41][42][43][44][45] describing the costs of OPAT over the past 25 years. The bottom line is that cost per day ranged from $122 in 1984 [38] to $183 in 2000 [42] to $107 (excluding cost of IV lines and vancomycin therapeutic drug monitoring) in 2002 [45] (2010 values: $263, $234, and $135, respectively).…”